Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells

Clive S. Zent, Ronald P. Taylor, Margaret A. Lindorfer, Paul V. Beum, Betsy Laplant, Wenting Wu, Timothy G. Call, Deborah A. Bowen, Michael J. Conte, Lori A. Frederick, Brian K. Link, Sue E. Blackwell, Suresh Veeramani, Nisar A. Baig, David S. Viswanatha, George J. Weiner, Thomas E. Witzig

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Fingerprint

Dive into the research topics of 'Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells'. Together they form a unique fingerprint.

Medicine & Life Sciences